PL4188420T3 - Kompozycje i sposoby związane z leczeniem chorób - Google Patents

Kompozycje i sposoby związane z leczeniem chorób

Info

Publication number
PL4188420T3
PL4188420T3 PL22712997.0T PL22712997T PL4188420T3 PL 4188420 T3 PL4188420 T3 PL 4188420T3 PL 22712997 T PL22712997 T PL 22712997T PL 4188420 T3 PL4188420 T3 PL 4188420T3
Authority
PL
Poland
Prior art keywords
diseases
compositions
treatment
methods related
methods
Prior art date
Application number
PL22712997.0T
Other languages
English (en)
Inventor
William Stimson
Original Assignee
ILC Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ILC Therapeutics Limited filed Critical ILC Therapeutics Limited
Publication of PL4188420T3 publication Critical patent/PL4188420T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL22712997.0T 2021-02-17 2022-02-16 Kompozycje i sposoby związane z leczeniem chorób PL4188420T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2102261.1A GB202102261D0 (en) 2021-02-17 2021-02-17 Compositions and methods relating to the treatment of diseases
PCT/GB2022/050406 WO2022175651A1 (en) 2021-02-17 2022-02-16 Compositions and methods relating to the treatment of diseases

Publications (1)

Publication Number Publication Date
PL4188420T3 true PL4188420T3 (pl) 2024-10-14

Family

ID=75339037

Family Applications (1)

Application Number Title Priority Date Filing Date
PL22712997.0T PL4188420T3 (pl) 2021-02-17 2022-02-16 Kompozycje i sposoby związane z leczeniem chorób

Country Status (13)

Country Link
US (1) US20240124545A1 (pl)
EP (1) EP4188420B1 (pl)
JP (1) JP2024507313A (pl)
KR (1) KR20230146504A (pl)
CN (1) CN116568318A (pl)
AU (1) AU2022223363A1 (pl)
CA (1) CA3190362A1 (pl)
ES (1) ES2981369T3 (pl)
GB (1) GB202102261D0 (pl)
HR (1) HRP20240992T1 (pl)
HU (1) HUE067796T2 (pl)
PL (1) PL4188420T3 (pl)
WO (1) WO2022175651A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523984B (zh) * 2024-11-27 2026-01-30 东莞市东南部中心医院(东莞市东南部中医医疗服务中心、广东医科大学附属东莞第一医院) 吐根碱在制备抗轮状病毒药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006526022A (ja) * 2003-05-23 2006-11-16 ペスカ バイオメディカル ラボラトリーズ, インク. 重症急性呼吸器症候群及び他のウィルス感染の治療のためのインターフェロンの使用
WO2006111745A2 (en) * 2005-04-20 2006-10-26 Viragen Incorporated Composition and method for treating viral infection
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
AU2019276776B2 (en) * 2018-06-01 2025-12-11 ILC Therapeutics Limited Compositions and methods relating to the treatment of diseases
PL4121092T3 (pl) * 2020-03-16 2024-08-19 Ilc Therapeutics Ltd Hybrydowe interferony do leczenia zakażeń wirusowych

Also Published As

Publication number Publication date
CN116568318A (zh) 2023-08-08
WO2022175651A9 (en) 2022-11-03
EP4188420A1 (en) 2023-06-07
CA3190362A1 (en) 2022-08-25
AU2022223363A1 (en) 2023-03-23
US20240124545A1 (en) 2024-04-18
ES2981369T3 (es) 2024-10-08
JP2024507313A (ja) 2024-02-19
HRP20240992T1 (hr) 2024-10-25
EP4188420B1 (en) 2024-06-05
GB202102261D0 (en) 2021-03-31
WO2022175651A1 (en) 2022-08-25
HUE067796T2 (hu) 2024-11-28
EP4188420C0 (en) 2024-06-05
KR20230146504A (ko) 2023-10-19

Similar Documents

Publication Publication Date Title
IL283042A (en) Compounds and compositions for treating conditions associated with nlrp activity
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
EP4146229A4 (en) COMPOSITIONS AND METHODS FOR TREATING POMPE DISEASE
EP4003299A4 (en) Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
EP3592345A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP4072574A4 (en) THERAPEUTIC CELL COMPOSITIONS AND METHODS OF PRODUCTION AND METHODS OF USE THEREOF
EP4149453A4 (en) COMBINATION TREATMENT OF LIVER DISEASES
EP4352231A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH ANGPTL4
EP3737379A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISEASES
EA201792341A1 (ru) Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
EP4412620A4 (en) OLIGOSACCHARIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF INFLAMMATORY LUNG DISEASES
EP4003006A4 (en) Compositions and methods of using multipotent stem cells to reduce disease and enhance wellness
IL311867A (en) Trem compositions and methods of use
EP4413032A4 (en) TREATMENT OF MAST CELL DISORDERS
EP4267163A4 (en) COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS
EP4384220A4 (en) Compositions and methods for treatment of cancer
EP4313024A4 (en) Treatment of inflammatory diseases
IL308083A (en) Methods and compositions for treatment of diabetic retinopathy and related conditions
IL299632A (en) Inflammatory disease treatment using anti-tissue factor antibodies
HUE067796T2 (hu) Összetételek és eljárások betegségek kezelésére
EP4007610A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALPHA-THALASSEMIA
EP4561557A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS
EP4412632A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISEASE
EP4415737A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF SKIN CONDITIONS
IL310210A (en) Methods for inhibiting the progression of oxidative retinal diseases